Gilead (NASDAQ: GILD) CMO gains 8,530 shares from performance award

Rhea-AI Filing Summary

Gilead Sciences Chief Medical Officer Dietmar Berger acquired 8,530 shares of common stock at no cost through a grant/award transaction. These shares relate to specific tranches of performance share awards originally granted on March 10, 2025.

The performance-vesting requirement for these tranches was satisfied on February 27, 2026, when the Compensation and Talent Committee certified that the performance goals were met. Following this award, Berger directly holds a total of 17,912 Gilead common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berger Dietmar

(Last) (First) (Middle)

333 LAKESIDE DR.

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		A(1)		8,530	A	$0	17,912	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2025. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.

Remarks:

	/s/ Edward S. Son by Power of Attorney for Dietmar Berger	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Gilead Sciences (GILD) report for Dietmar Berger?

Gilead Sciences reported that Chief Medical Officer Dietmar Berger acquired 8,530 shares of common stock via a grant/award. These shares came from performance share award tranches that vested after performance goals were certified by the board’s Compensation and Talent Committee.

How many Gilead (GILD) shares does Dietmar Berger hold after this Form 4?

After this transaction, Dietmar Berger directly holds 17,912 shares of Gilead common stock. The increase reflects 8,530 shares tied to performance share awards, which vested once the Compensation and Talent Committee certified that the specified performance goals had been attained.

Was cash paid for the Gilead (GILD) shares acquired by Dietmar Berger?

No cash was paid for these Gilead shares; the transaction price per share was reported as $0.0000. The 8,530 shares were received through vesting of performance-based equity awards, following satisfaction of both performance and service-vesting conditions set in the original grant.

What is the origin of the 8,530 Gilead (GILD) shares awarded to Dietmar Berger?

The 8,530 shares come from specific tranches of performance share awards granted to Dietmar Berger on March 10, 2025. These tranches were subject to performance and service vesting, with performance conditions met once the Compensation and Talent Committee certified goal attainment on February 27, 2026.

Who approved the vesting of Dietmar Berger’s Gilead (GILD) performance shares?

The vesting was approved when Gilead’s Compensation and Talent Committee certified that the performance goals had been attained. This committee, part of the board of directors, determined performance for the relevant tranches, enabling the 8,530 performance-based shares to be credited to Berger’s direct holdings.